Cost-effectiveness of pharmaceutical management for osteoarthritis pain: A systematic review of the literature and recommendations for future economic evaluation

Drugs and Aging

Volumn 30, Issue 5, 2013, Pages 277-284

  Xie, Feng ^a   Tanvejsilp, Pimwara ^a   Campbell, Kaitryn ^a   Gaebel, Kathryn ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CHONDROITIN; CORTICOSTEROID; DICLOFENAC; ETORICOXIB; GLUCOSAMINE; GLUCOSAMINE SULFATE; HYALURONIC ACID; HYDROMORPHONE; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR;

ANALGESIA; ARTHRALGIA; BIBLIOGRAPHIC DATABASE; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; HEALTH ECONOMICS; HUMAN; INFORMATION RETRIEVAL; MEDLINE; OSTEOARTHRITIS; OSTEOARTHRITIS PAIN; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PHYSICAL DISABILITY; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW;

EID: 84876897455     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0062-3     Document Type: Review

References (26)

1. Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford). 2005;44(1):7-16. (Pubitemid 40136474)
2. Sharma L, Kapoor D, Issa S. Epidemiology of osteoarthritis: an update. Curr Opin Rheumatol. 2006;18(2):147-56. (Pubitemid 43740387)
3. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137-62. (Pubitemid 351222155)
4. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-55. (Pubitemid 37500619)
5. Reginster JY, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. Rheumatology (Oxford). 2007;46(5):731-5. (Pubitemid 47061700)
6. Grey matters: a practical search tool for evidence-based medicine. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011.
7. Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41(1):32-44.
8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. (Pubitemid 26120810)
9. Black C, Clar C, Henderson R, MacEachern C, McNamee P, Quayyum Z, et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2009;13(52):1-148.
10. Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthr Cartil. 2002;10(7):518-27. (Pubitemid 34919066)
11. Bruyere O, Scholtissen S, Neuprez A, Hiligsmann M, Toukouki A, Reginster JY. Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. J Med Econ. 2009;12(4):356-60.
12. Scholtissen S, Bruyere O, Neuprez A, Severens JL, Herrero-Beaumont G, Rovati L, et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract. 2010;64(6):756-62.
13. Castelnuovo E, Cross P, Mt-Isa S, Spencer A, Underwood M, TOIB study team. Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain; the TOIB study [ISRCTN: 79353052. Rheumatology (Oxford). 2008;47(7):1077-81. (Pubitemid 351865938)
14. Marshall DA, Strauss ME, Pericak D, Buitendyk M, Codding C, Torrance GW. Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. Am J Manag Care. 2006;12(4):205-14.
15. Herrero-Beaumont G, Ivorra JA, Del Carmen TM, Blanco FJ, Benito P, Martin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthr Rheum. 2007;56(2):555-67.
16. Kahan A, Uebelhart D, De VF, Delmas PD, Reginster JY. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthr Rheum. 2009;60(2):524-33.
17. Underwood M, Ashby D, Carnes D, Castelnuovo E, Cross P, Harding G, et al. Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. Health Technol Assess. 2008;12(22):iii-iv, ix-155.
18. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-40. (Pubitemid 19037656)
19. Yen ZS, Lai MS, Wang CT, Chen LS, Chen SC, Chen WJ, et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J Rheumatol. 2004;31(9):1797-803.
20. Kamath CC, Kremers HM, Vanness DJ, O'Fallon WM, Cabanela RL, Gabriel SE. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health. 2003;6(2):144-57. (Pubitemid 36403132)
21. Contreras-Hernandez I, Mould-Quevedo JF, Torres-Gonzalez R, Goycochea-Robles MV, Pacheco-Dominguez RL, Sanchez-Garcia S, et al. Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs cyclooxygenase-2 selective inhibitors. Cost Eff Res Allocation. 2008;6:21.
22. Ward A, Bozkaya D, Fleischmann J, Dubois D, Sabatowski R, Caro JJ. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Curr Med Res Opin. 2007;23(10):2333-45. (Pubitemid 350033435)
23. Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ. 2009;339:b2538.
24. Brereton N, Winn B, Akehurst R. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. J Med Econ. 2012;15(3):465-72.
25. Hays RD, Stewart AL. Measuring functioning and well-being: the Medical Outcomes Study approach. Durham: Duke University Press; 1992.
26. World Health organization. Chronic rheumatic conditions. Department of Chronic Disease and health promotion, 2011. http://www.who.int/chp/topics/ rheumatic/en. Accessed 24 May 2012.